MedDRA preferred term

Injection site extravasation: adverse event reports recording this term

12,301 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

12,301
reports recording the term: 0.1% of all reports; 186
reports, 12 months to June 2026: 239 in the 12 months before; 21%
marked serious by the reporter: 57.4% across all reports; 0.5%
record death among outcomes, as reported: 9.1% across all reports

"Injection site extravasation" is a MedDRA preferred term recorded in 12,301 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

186 reports recorded it in the 12 months to June 2026, down 22% from 239 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 21% are marked serious, 0.5% include death among the outcomes and 7.9% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Humira, Enbrel and Bydureon. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Humira	—	1,687	0.3%
Enbrel	Tumor necrosis factor blocker	1,517	0.3%
Bydureon	—	1,469	7.5%
Bydureon Bcise	—	1,285	10%
Byetta	GLP-1 receptor agonist	458	1%
Lexiscan(r) (regadenoson)	Adenosine receptor agonist	356	8.5%
Vedolizumab	Integrin receptor antagonist	300	0.5%
Wegovy	GLP-1 receptor agonist	299	1.5%
Repatha	PCSK9 inhibitor	186	0.1%
Ajovy	—	165	1.7%
Dupixent	Interleukin-4 receptor alpha antagonist	157	0%
Sublocade	Partial opioid agonist	141	2.8%
Actemra	Interleukin-6 receptor antagonist	138	0.2%
Rituximab	CD20-directed cytolytic antibody	137	0.1%
Aimovig	—	120	0.2%
Boniva	—	120	0.7%
Omnitrope	Recombinant human growth hormone	116	1%
Avonex	Interferon beta	111	0.1%
Cosentyx	Interleukin-17A antagonist	110	0.1%
Praluent	PCSK9 inhibitor	104	0.5%
Remicade	Tumor necrosis factor blocker	98	0.1%
Forteo	Parathyroid hormone analog	94	0.1%
Hizentra	Human immunoglobulin G	90	0.4%
Lisinopril	Angiotensin converting enzyme inhibitor	87	0.2%
Prednisone	Corticosteroid	85	0%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Tumor necrosis factor blocker	1,702	0.2%	0%
GLP-1 receptor agonist	876	0.2%	0%
Adenosine receptor agonist	356	7.1%	4.3%
Integrin receptor antagonist	319	0.1%	0.1%
CD20-directed cytolytic antibody	309	0.1%	0%
PCSK9 inhibitor	290	0.2%	0.1%
Insulin analog	195	0.1%	0%
Interleukin-4 receptor alpha antagonist	171	0%	0.1%
Interleukin-6 receptor antagonist	146	0.1%	0%
Partial opioid agonist	141	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%35

2 to 111.3%163

12 to 171.3%162

18 to 4411.8%1,456

45 to 6424.8%3,055

65 to 7412.8%1,572

75 and over5.8%718

Age not given41.8%5,140

Patient sex

Female61.4%7,547

Male30.4%3,741

Not given8.2%1,013

Grey bar: all 20,646,523 reports in the database. 88.2% of these reports give the United States as the country.

Questions about "Injection site extravasation"

What does "Injection site extravasation" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record injection site extravasation?

12,301 reports through June 2026 (0.1% of all reports), 186 of them in the latest 12 months.

Which drugs appear most often in these reports?

Humira (1,687), Enbrel (1,517), Bydureon (1,469), Bydureon Bcise (1,285) and Byetta (458). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.